{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T01:57:08Z","timestamp":1788573428756,"version":"build-2803163510"},"reference-count":30,"publisher":"Public Library of Science (PLoS)","issue":"2","license":[{"start":{"date-parts":[[2017,2,13]],"date-time":"2017-02-13T00:00:00Z","timestamp":1486944000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005923","name":"International Association for the Study of Lung Cancer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005923","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0172209","type":"journal-article","created":{"date-parts":[[2017,2,13]],"date-time":"2017-02-13T19:44:37Z","timestamp":1487015077000},"page":"e0172209","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":19,"title":["Potential effect of spliceosome inhibition in small cell lung cancer irrespective of the MYC status"],"prefix":"10.1371","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0842-8832","authenticated-orcid":true,"given":"Kenichi","family":"Suda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leslie","family":"Rozeboom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim","family":"Ellison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher J.","family":"Rivard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuya","family":"Mitsudomi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fred R.","family":"Hirsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2017,2,13]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1016\/S0140-6736(16)31473-8","article-title":"New and emerging targeted treatments in advanced non-small-cell lung cancer","volume":"388","author":"FR Hirsch","year":"2016","journal-title":"Lancet"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1038\/ng.2396","article-title":"Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer","volume":"44","author":"M Peifer","year":"2012","journal-title":"Nat Genet"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1038\/ng.2405","article-title":"Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer","volume":"44","author":"CM Rudin","year":"2012","journal-title":"Nat Genet"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"17034","DOI":"10.1073\/pnas.1207310109","article-title":"A framework for identification of actionable cancer genome dependencies in small cell lung cancer","volume":"109","author":"ML Sos","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1002\/jcb.240630516","article-title":"MYC family DNA amplification in 126 tumor cell lines from patients with small cell lung cancer","volume":"24","author":"BE Johnson","year":"1996","journal-title":"J Cell Biochem Suppl"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1038\/nrc3984","article-title":"MYC: connecting selective transcriptional control to global RNA production","volume":"15","author":"TR Kress","year":"2015","journal-title":"Nat Rev Cancer"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1177\/1947601910377494","article-title":"Therapeutic Targeting of Myc","volume":"1","author":"EV Prochownik","year":"2010","journal-title":"Genes Cancer"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1038\/nature14985","article-title":"The spliceosome is a therapeutic vulnerability in MYC-driven cancer","volume":"525","author":"TY Hsu","year":"2015","journal-title":"Nature"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1002\/ijc.2910410325","article-title":"Establishment and characterization of cisplatin-resistant sublines of human lung cancer cell lines","volume":"41","author":"WS Hong","year":"1988","journal-title":"Int J Cancer"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s11010-011-1199-1","article-title":"Long-term cisplatin exposure impairs autophagy and causes cisplatin resistance in human lung cancer cells","volume":"364","author":"B Sirichanchuen","year":"2012","journal-title":"Mol Cell Biochem"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1002\/ijc.28737","article-title":"The insulin-like growth factor 1 receptor causes acquired resistance to erlotinib in lung cancer cells with the wild-type epidermal growth factor receptor","volume":"135","author":"K Suda","year":"2014","journal-title":"Int J Cancer"},{"key":"ref12","first-page":"301","article-title":"Altered Ca2+-homeostasis of cisplatin-treated and low level resistant non-small-cell and small-cell lung cancer cells","volume":"31","author":"K Schrodl","year":"2009","journal-title":"Cell Oncol"},{"key":"ref13","first-page":"2913","article-title":"Establishment and identification of small cell lung cancer cell lines having classic and variant features","volume":"45","author":"DN Carney","year":"1985","journal-title":"Cancer Res"},{"key":"ref14","first-page":"3809","article-title":"DNA breakage in human lung carcinoma cells and nuclei that are naturally sensitive or resistant to etoposide and teniposide","volume":"46","author":"BH Long","year":"1986","journal-title":"Cancer Res"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"3004","DOI":"10.1038\/sj.onc.1202746","article-title":"MYC oncogenes and human neoplastic disease","volume":"18","author":"CE Nesbit","year":"1999","journal-title":"Oncogene"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1016\/j.cell.2014.02.031","article-title":"Genetic and clonal dissection of murine small cell lung carcinoma progression by genome sequencing","volume":"156","author":"DG McFadden","year":"2014","journal-title":"Cell"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1126\/science.1212728","article-title":"A SUMOylation-dependent transcriptional subprogram is required for Myc-driven tumorigenesis","volume":"335","author":"JD Kessler","year":"2012","journal-title":"Science"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1186\/1471-2407-14-944","article-title":"Identification of synthetic lethality of PRKDC in MYC-dependent human cancers by pooled shRNA screening","volume":"14","author":"Z Zhou","year":"2014","journal-title":"BMC Cancer"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1016\/j.ccell.2014.10.019","article-title":"Targeting transcriptional addictions in small cell lung cancer with a covalent CDK7 inhibitor","volume":"26","author":"CL Christensen","year":"2014","journal-title":"Cancer Cell"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"3292","DOI":"10.18632\/oncotarget.3203","article-title":"MYC is a critical target of FBXW7","volume":"6","author":"M Sato","year":"2015","journal-title":"Oncotarget"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1038\/nm.4213","article-title":"PIM1 kinase inhibition as a targeted therapy against triple-negative breast tumors with elevated MYC expression","volume":"22","author":"D Horiuchi","year":"2016","journal-title":"Nat Med"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/nature14351","article-title":"MYC regulates the core pre-mRNA splicing machinery as an essential step in lymphomagenesis","volume":"523","author":"CM Koh","year":"2015","journal-title":"Nature"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1101\/gad.212548.112","article-title":"Genome-wide RNAi screens in human brain tumor isolates reveal a novel viability requirement for PHF5A","volume":"27","author":"CG Hubert","year":"2013","journal-title":"Genes Dev"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"945","DOI":"10.3324\/haematol.2014.122069","article-title":"Targeting the spliceosome in chronic lymphocytic leukemia with the macrolides FD-895 and pladienolide-B","volume":"100","author":"MK Kashyap","year":"2015","journal-title":"Haematologica"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1158\/0008-5472.CAN-12-2501","article-title":"Targeting the deregulated spliceosome core machinery in cancer cells triggers mTOR blockade and autophagy","volume":"73","author":"V Quidville","year":"2013","journal-title":"Cancer Res"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1101\/gad.237206.113","article-title":"An integrative analysis of colon cancer identifies an essential function for PRPF6 in tumor growth","volume":"28","author":"AS Adler","year":"2014","journal-title":"Genes Dev"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"6296","DOI":"10.1158\/1078-0432.CCR-13-0485","article-title":"Phase I pharmacokinetic and pharmacodynamic study of the first-in-class spliceosome inhibitor E7107 in patients with advanced solid tumors","volume":"19","author":"FA Eskens","year":"2013","journal-title":"Clin Cancer Res"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1007\/s10637-013-0046-5","article-title":"A phase I, open-label, single-arm, dose-escalation study of E7107, a precursor messenger ribonucleic acid (pre-mRNA) splicesome inhibitor administered intravenously on days 1 and 8 every 21 days to patients with solid tumors","volume":"32","author":"DS Hong","year":"2014","journal-title":"Invest New Drugs"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1111\/his.12622","article-title":"Myc protein expression correlates with MYC amplification in small-cell lung carcinoma","volume":"67","author":"DH Hwang","year":"2015","journal-title":"Histopathology"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"31014","DOI":"10.18632\/oncotarget.8826","article-title":"Growth suppression by MYC inhibition in small cell lung cancer cells with TP53 and RB1 inactivation","volume":"7","author":"FP Fiorentino","year":"2016","journal-title":"Oncotarget"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0172209","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,9]],"date-time":"2020-05-09T14:31:00Z","timestamp":1589034660000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0172209"}},"subtitle":[],"editor":[{"given":"Aamir","family":"Ahmad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2017,2,13]]},"references-count":30,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2017,2,13]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0172209","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,2,13]]}}}